07:00 , Oct 18, 2012 |  BC Innovations  |  Targets & Mechanisms

EZH2 moves

Epizyme Inc. and GlaxoSmithKline plc have independently reported small molecule inhibitors of histone methyltransferase enhancer of zeste homolog 2 that showed efficacy in preclinical models of lymphomas with activating mutations of the target.1,2 Both companies...